Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Blood (2023) 142 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2023-181233

Published: 2023

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

Blood (2023) 142 (Supplement 1): 205.

https://doi.org/10.1182/blood-2023-177673

Published: 2023

Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Blood (2022) 140 (Supplement 1): 397–399.

https://doi.org/10.1182/blood-2022-157988

Published: 2022

Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Blood (2022) 140 (Supplement 1): 10137–10139.

https://doi.org/10.1182/blood-2022-158146

Published: 2022

Journal Articles

Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis

Blood (2021) 138 (Supplement 1): 4109.

https://doi.org/10.1182/blood-2021-146908

Published: 2021

Journal Articles

Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen

Martina Di Trani, Francesca Ricci, Martina Sollini, Eleonora Calabretta, Vanessa Cristaldi, Stefanos Bonovas, Fabrizio Marino, Rita Mazza, Alessio Bruscaggin, Maria Cristina Pirosa, Arturo Chiti, Davide Rossi, Armando Santoro, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 3504.

https://doi.org/10.1182/blood-2021-151362

Published: 2021

Journal Articles

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 2025.

https://doi.org/10.1182/blood-2019-130786

Published: 2019

Journal Articles

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, MD, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, Flavia Salvi, Antonella Anastasia, MD, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, MD, Anna Marina Liberati, MD, Nicola Di Renzo, MD, Luca Castagna, MD, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2018-99-118931

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Armando Santoro, MD, Luca Castagna, MD, Massimo Magagnoli, MD, Stefania Bramanti, MD, Jacopo Mariotti, MD, Rita Mazza, MD, Lucia Morello, MD, Francesca Ricci, MD, Barbara Sarina, MD, Chiara De Philippis, MD, Simona Sica, MD, Marcello Rodari, MD, Martina Sollini, MD, Margarita Kirienko, MD, Laura Giordano, Arturo Chiti, MD, Paolo Corradini, MD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2018-99-118127

Published: 2018

Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Blood (2018) 132 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2018-99-115313

Published: 2018

Journal Articles

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, MD, Flavia Salvi, MD, Antonella Anastasia, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, Anna Marina Liberati, MD, Nicola Di Renzo, Luca Castagna, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2015) 126 (23): 581.

https://doi.org/10.1182/blood.V126.23.581.581

Published: 2015

Journal Articles

The PI3K-δ Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts

Silvia L Locatelli, PhD, Silvia Tartari, PhD, Luca Castagna, MD, Rita Mazza, Srikant Viswanadha, PhD, Peter Sportelli, Swaroop Vakkalanka, PhD, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2014) 124 (21): 4486.

https://doi.org/10.1182/blood.V124.21.4486.4486

Published: 2014

Journal Articles

Pilot Study with Lenalidomide in Patients with POEMS Syndrome

Andrea Nozza, MD, Fabrizia Terenghi, Rita Mazza, Eduardo Nobile Orazio, Fausto Adami, Giampaolo Merlini, MD, Chiara Briani, Giovanni Palladini, Mariella Grasso, Sara Gandolfi, MD, Carmelo Carlo-Stella, MD, Armando Santoro

Blood (2011) 118 (21): 4612.

https://doi.org/10.1182/blood.V118.21.4612.4612

Published: 2011

Journal Articles

Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy

Massimo Magagnoli, Katia Marzo, MD, Monica Balzarotti, Marcello Rodari, Rita Mazza, Laura Giordano, MD, Sara Gandolfi, MD, Stefania Bramanti, Antonella Anastasia, MD, Fabio Romano Lutman, MD, Arturo Chiti, MD, Armando Santoro

Blood (2011) 118 (21): 93.

https://doi.org/10.1182/blood.V118.21.93.93

Published: 2011

Journal Articles

Result of FDG PET Imaging After Chemotherapy +/− Immunotherapy Is a Significant and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: Survey From a Single Institution

Massimo Magagnoli, Rita Mazza, Sara Gandolfi, Marcello Rodari, Laura Giordano, MD, Antonella Anastasia, MD, Egesta Lopci, Arturo Chiti, Armando Santoro, Monica Balzarotti

Blood (2011) 118 (21): 2674.

https://doi.org/10.1182/blood.V118.21.2674.2674

Published: 2011

Journal Articles

Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL)

Massimo Magagnoli, Monica Balzarotti, Antonella Anastasia, Rita Mazza, Laura Giordano, MD, Luca Castagna, Michele Spina, MD, Alessandra Romano, Stefania Bramanti, Armando Santoro

Blood (2010) 116 (21): 1761.

https://doi.org/10.1182/blood.V116.21.1761.1761

Published: 2010

Journal Articles

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV).

Antonella Anastasia, MD, Monica Balzarotti, Massimo Magagnoli, MD, Michele Spina, MD, Rita Mazza, MD, L. Castagna, Andrea Nozza, Stefania Bramanti, md, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro

Blood (2009) 114 (22): 1213.

https://doi.org/10.1182/blood.V114.22.1213.1213

Published: 2009

Journal Articles

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Rita Mazza, MD, Stefano Luminari, Massimo Magagnoli, MD, Michele Spina, MD, Teodoro Chisesi, MD, Antonio Pinto, MD, Massimo Federico, MD, Antonella Anastasia, MD, Arturo Chiti, MD, Mariagrazia Michieli, MD, Francesco Angrilli, MD, Luca Castagna, Giampaolo Marcacci, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro, Monica Balzarotti

Blood (2009) 114 (22): 3707.

https://doi.org/10.1182/blood.V114.22.3707.3707

Published: 2009

Journal Articles

Intensified CHOP (ICHOP) +/− Rituximab in Primary Mediastinal Diffuse Large B Cell Lymphoma (PMBCL): The Role of Doxorubicin/Cyclophosphamide Dose-Intensity

Rita Mazza, MD, Monica Demarco, MD, Michele Spina, MD, Massimo Magagnoli, MD, Luca Castagna, MD, Licia Siracusano, MD, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro, MD, Monica Balzarotti, MD

Blood (2008) 112 (11): 3593.

https://doi.org/10.1182/blood.V112.11.3593.3593

Published: 2008

NARROW

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis

Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

The PI3K-δ Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts

Pilot Study with Lenalidomide in Patients with POEMS Syndrome

Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy

Result of FDG PET Imaging After Chemotherapy +/− Immunotherapy Is a Significant and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: Survey From a Single Institution

Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL)

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV).

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Intensified CHOP (ICHOP) +/− Rituximab in Primary Mediastinal Diffuse Large B Cell Lymphoma (PMBCL): The Role of Doxorubicin/Cyclophosphamide Dose-Intensity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only